<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04567459</url>
  </required_header>
  <id_info>
    <org_study_id>202000035A3</org_study_id>
    <nct_id>NCT04567459</nct_id>
  </id_info>
  <brief_title>The Effect of Nutrition for the Colorectal Cancer Patients Receiving Chemotherapy-randomized Controlled Study</brief_title>
  <official_title>The Effect of Nutrition for the Colorectal Cancer Patients Receiving Chemotherapy-randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hanben Enterprise</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chang Gung Memorial Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      We use clinical trial to explore the effect of nutrition support in colorectal cancer&#xD;
      patients receiving postoperative adjuvant chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Colorectal cancer is the most common cancer in Taiwan. Side effects induced by postoperative&#xD;
      adjuvant chemotherapy will affect nutrition status and may delay treatment and affect&#xD;
      prognosis. Sarcopenia may be noted in some patients and increase the toxicities of&#xD;
      chemotherapy. The studies of intervention include nutrition consultant and treatment like&#xD;
      protein, fish oil or Vitamin D supplement. Premium amino acids include multiple amino acids&#xD;
      and organic Selenium and have effect in inhibition of tumor proliferation according to&#xD;
      colorectal cancer cell and animal experiments.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">January 27, 2021</start_date>
  <completion_date type="Anticipated">February 22, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 22, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of adverse event</measure>
    <time_frame>2 weeks after chemotherapy</time_frame>
    <description>Evaluation of adverse event(Grade 1-4) between control group and experimental group before every chemotherapy(total 12 times)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>1)Nutrition assessment</measure>
    <time_frame>2 weeks after chemotherapy</time_frame>
    <description>albumin level between two group before every chemotherapy(total 12 times)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>2)Nutrition assessment</measure>
    <time_frame>2 weeks after chemotherapy</time_frame>
    <description>pre-albumin level between two group before every chemotherapy(total 12 times)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>1)Sarcopenia assessment muscle power</measure>
    <time_frame>At 1st cycle of chemotherapy (each cycle is 2 weeks).</time_frame>
    <description>1-1)Assessment with Grip strength(Kg)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>1)Sarcopenia assessment muscle power</measure>
    <time_frame>At 12th cycle of chemotherapy (each cycle is 2 weeks).</time_frame>
    <description>1-2)Assessment with Grip strength(Kg)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>2)Sarcopenia assessment muscle power</measure>
    <time_frame>At 1st cycle of chemotherapy (each cycle is 2 weeks).</time_frame>
    <description>2-1)Assessment with ASM/heigh2(Kg/m2)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>2)Sarcopenia assessment muscle power</measure>
    <time_frame>At 12st cycle of chemotherapy (each cycle is 2 weeks).</time_frame>
    <description>2-2)Assessment with ASM/heigh2(Kg/m2)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>3)Sarcopenia assessment</measure>
    <time_frame>At 1st cycle of chemotherapy (each cycle is 2 weeks).</time_frame>
    <description>3-1)Assessment with speed(m/s)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>3)Sarcopenia assessment</measure>
    <time_frame>At 12th cycle of chemotherapy (each cycle is 2 weeks).</time_frame>
    <description>3-2)Assessment with speed(m/s)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>4)Sarcopenia assessment</measure>
    <time_frame>At 1st cycle of chemotherapy (each cycle is 2 weeks).</time_frame>
    <description>4-1)Assessment with DXA(g/cm2)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>4)Sarcopenia assessment</measure>
    <time_frame>At 12th cycle of chemotherapy (each cycle is 2 weeks).</time_frame>
    <description>4-2)Assessment with DXA(g/cm2)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>5)Sarcopenia assessment</measure>
    <time_frame>At 6th cycle of chemotherapy (each cycle is 2 weeks).</time_frame>
    <description>5-1)Assessment with abdominal CT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>5)Sarcopenia assessment</measure>
    <time_frame>At 12th cycle of chemotherapy (each cycle is 2 weeks).</time_frame>
    <description>5-2)Assessment with abdominal CT</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>control group: chemotherapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>experimental group: chemotherapy and nutrition support</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Premium amino acids 1pc bid for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Premium Amino Acids</intervention_name>
    <description>after Chemotherapy ang surgery one pack of Premium Amino Acids in the morning and evening</description>
    <arm_group_label>experimental group: chemotherapy and nutrition support</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 20&#xD;
&#xD;
          -  Radical operation for stage III and stage II with high risk colorectal cancer&#xD;
&#xD;
          -  Agree to join the trial and sign the informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable to receive chemotherapy&#xD;
&#xD;
          -  Unstable vital sign&#xD;
&#xD;
          -  Not suitable after evaluation by Principal Investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wan-Hsiang Hu, M.D.</last_name>
    <phone>886-975056227</phone>
    <email>gary.hu0805@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital,Kaohsiung</name>
      <address>
        <city>Kaohsiung</city>
        <zip>833</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wan Hsiang Hu</last_name>
      <phone>+886-7-7317123</phone>
      <phone_ext>8008</phone_ext>
      <email>gary.hu0805@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Chiang CJ, Lo WC, Yang YW, You SL, Chen CJ, Lai MS. Incidence and survival of adult cancer patients in Taiwan, 2002-2012. J Formos Med Assoc. 2016 Dec;115(12):1076-1088. doi: 10.1016/j.jfma.2015.10.011. Epub 2016 Jan 16.</citation>
    <PMID>26786251</PMID>
  </reference>
  <reference>
    <citation>Andr√© T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, Bonetti A, Clingan P, Bridgewater J, Rivera F, de Gramont A. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009 Jul 1;27(19):3109-16. doi: 10.1200/JCO.2008.20.6771. Epub 2009 May 18.</citation>
    <PMID>19451431</PMID>
  </reference>
  <reference>
    <citation>Casadaban L, Rauscher G, Aklilu M, Villenes D, Freels S, Maker AV. Adjuvant chemotherapy is associated with improved survival in patients with stage II colon cancer. Cancer. 2016 Nov 15;122(21):3277-3287. doi: 10.1002/cncr.30181. Epub 2016 Jul 15.</citation>
    <PMID>27417445</PMID>
  </reference>
  <reference>
    <citation>Gelibter AJ, Caponnetto S, Urbano F, Emiliani A, Scagnoli S, Sirgiovanni G, Napoli VM, Cortesi E. Adjuvant chemotherapy in resected colon cancer: When, how and how long? Surg Oncol. 2019 Sep;30:100-107. doi: 10.1016/j.suronc.2019.06.003. Epub 2019 Jul 2. Review.</citation>
    <PMID>31500770</PMID>
  </reference>
  <reference>
    <citation>Jung HW, Kim JW, Kim JY, Kim SW, Yang HK, Lee JW, Lee KW, Kim DW, Kang SB, Kim KI, Kim CH, Kim JH. Effect of muscle mass on toxicity and survival in patients with colon cancer undergoing adjuvant chemotherapy. Support Care Cancer. 2015 Mar;23(3):687-94. doi: 10.1007/s00520-014-2418-6. Epub 2014 Aug 28.</citation>
    <PMID>25163434</PMID>
  </reference>
  <reference>
    <citation>Chen LK, Liu LK, Woo J, Assantachai P, Auyeung TW, Bahyah KS, Chou MY, Chen LY, Hsu PS, Krairit O, Lee JS, Lee WJ, Lee Y, Liang CK, Limpawattana P, Lin CS, Peng LN, Satake S, Suzuki T, Won CW, Wu CH, Wu SN, Zhang T, Zeng P, Akishita M, Arai H. Sarcopenia in Asia: consensus report of the Asian Working Group for Sarcopenia. J Am Med Dir Assoc. 2014 Feb;15(2):95-101. doi: 10.1016/j.jamda.2013.11.025.</citation>
    <PMID>24461239</PMID>
  </reference>
  <reference>
    <citation>Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruy√®re O, Cederholm T, Cooper C, Landi F, Rolland Y, Sayer AA, Schneider SM, Sieber CC, Topinkova E, Vandewoude M, Visser M, Zamboni M; Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019 Jan 1;48(1):16-31. doi: 10.1093/ageing/afy169. Erratum in: Age Ageing. 2019 Jul 1;48(4):601.</citation>
    <PMID>30312372</PMID>
  </reference>
  <reference>
    <citation>Bano G, Trevisan C, Carraro S, Solmi M, Luchini C, Stubbs B, Manzato E, Sergi G, Veronese N. Inflammation and sarcopenia: A systematic review and meta-analysis. Maturitas. 2017 Feb;96:10-15. doi: 10.1016/j.maturitas.2016.11.006. Epub 2016 Nov 13. Review.</citation>
    <PMID>28041587</PMID>
  </reference>
  <reference>
    <citation>Lin JX, Lin JP, Xie JW, Wang JB, Lu J, Chen QY, Cao LL, Lin M, Tu R, Zheng CH, Huang CM, Li P. Prognostic Value and Association of Sarcopenia and Systemic Inflammation for Patients with Gastric Cancer Following Radical Gastrectomy. Oncologist. 2019 Nov;24(11):e1091-e1101. doi: 10.1634/theoncologist.2018-0651. Epub 2019 Mar 25.</citation>
    <PMID>30910865</PMID>
  </reference>
  <reference>
    <citation>Tessier AJ, Chevalier S. An Update on Protein, Leucine, Omega-3 Fatty Acids, and Vitamin D in the Prevention and Treatment of Sarcopenia and Functional Decline. Nutrients. 2018 Aug 16;10(8). pii: E1099. doi: 10.3390/nu10081099. Review.</citation>
    <PMID>30115829</PMID>
  </reference>
  <reference>
    <citation>Mazzuca F, Roberto M, Arrivi G, Sarfati E, Schipilliti FM, Crimini E, Botticelli A, Di Girolamo M, Muscaritoli M, Marchetti P. Clinical Impact of Highly Purified, Whey Proteins in Patients Affected With Colorectal Cancer Undergoing Chemotherapy: Preliminary Results of a Placebo-Controlled Study. Integr Cancer Ther. 2019 Jan-Dec;18:1534735419866920. doi: 10.1177/1534735419866920.</citation>
    <PMID>31370717</PMID>
  </reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>August 26, 2020</study_first_submitted>
  <study_first_submitted_qc>September 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2020</study_first_posted>
  <last_update_submitted>January 26, 2021</last_update_submitted>
  <last_update_submitted_qc>January 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chang Gung Memorial Hospital</investigator_affiliation>
    <investigator_full_name>Wan-Hsiang Hu</investigator_full_name>
    <investigator_title>Attending physician</investigator_title>
  </responsible_party>
  <keyword>colorectal cancer</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Nutrition</keyword>
  <keyword>Sarcopenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

